Seizures Clinical Trials

Find Seizures Clinical Trials Near You

Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

The main purpose of this study is to understand the effects of continuing versus discontinuing antiseizure medications after a period of seizure-freedom. Physician guidelines endorse that after a period of seizure-freedom, the risk of another seizure may be low enough to allow patients to consider coming off antiseizure medication to see if they still need it. However, evidence is limited regarding how much continuing antiseizure medication still reduces seizures versus increases side effects after a patient has been treated for a while. This study will determine whether discontinuing antiseizure medications benefits patients.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Provision of signed and dated informed consent form

• Stated willingness to comply with all study procedures and availability for the duration of the study

• Diagnosis of epilepsy

• At least 2 years since participants most recent seizure

• At most 35% calculated 1-year post-discontinuation seizure risk, based upon the existing multivariable calculator if they are on only 1 ASM, otherwise no such restriction if they are more than 1 ASM

• Willingness to adhere to the study intervention

• Taking at least 1 antiseizure medication prior to enrollment

Locations
United States
Michigan
University of Michigan
RECRUITING
Ann Arbor
Contact Information
Primary
Samuel Terman, MD, MS
sterman@umich.edu
734-936-9020
Time Frame
Start Date: 2026-08
Estimated Completion Date: 2029-08
Participants
Target number of participants: 40
Treatments
Experimental: Discontinue antiseizure medications
Related Therapeutic Areas
Sponsors
Leads: University of Michigan
Collaborators: National Institute on Aging (NIA)

This content was sourced from clinicaltrials.gov